Chemotherapy: Satraplatin delays progression in prostate cancer

摘要

Prostate cancer is the second most common cancer in men worldwide. The FDA approved docetaxel in 2004 as first-line treatment for men with castrate-refractory prostate cancer (CRPC) and this is now the standard treatment for such patients. Patients with metastatic disease, however, eventually discontinue docetaxel treatment because of disease progression or toxic effects. It is therefore important to identify effective and well-tolerated treatments for patients with CRPC, whose experience disease progression after chemotherapy, as appropriate second-Line therapy is an important unmet medical need.